Furthermore, additional translational research is needed to demonstrate if the modulation of “upstream–downstream” targets of PKC-dependent pathway might be more effective than either agent alone and if this approach will be beneficial in altering tumor progression. The gene discussed is PRRT2; the disease is neoplasm.